1.
Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis
by Norbis, Luca
Expert review of anti-infective therapy, 2014, Vol.12 (5), p.633-647
2.
Paediatric tuberculosis
by Newton, Sandra M, Dr
The Lancet infectious diseases, 2008, Vol.8 (8), p.498-510
3.
Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis
by Lieberman, Tami D
Nature medicine, 2016, Vol.22 (12), p.1470-1474
4.
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
by Lawn, Stephen D, FRCP
The Lancet infectious diseases, 2013, Vol.13 (4), p.349-361
5.
Tuberculosis biomarkers discovery: developments, needs, and challenges
by Wallis, Robert S, Prof
The Lancet infectious diseases, 2013, Vol.13 (4), p.362-372
6.
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
by Aagaard, Claus
Nature medicine, 2011, Vol.17 (2), p.189-194
7.
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
by Imperial, Marjorie Z
Nature medicine, 2018, Vol.24 (11), p.1708-1715
8.
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis
by Gandhi, Neel R, Dr
The Lancet (British edition), 2010, Vol.375 (9728), p.1830-1843
9.
Publisher Correction: IFN-[gamma]-independent immune markers of Mycobacterium tuberculosis exposure
by Lu, Lenette L
Nature medicine, 2019, Vol.25 (7), p.1175
10.
Tuberculosis assays: past, present and future
by Chegou, Novel N
Expert review of anti-infective therapy, 2011, Vol.9 (4), p.457-469
11.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementat...
by Boehme, Catharina C, Dr
The Lancet (British edition), 2011, Vol.377 (9776), p.1495-1505
12.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
by Tameris, Michele D, Dr
The Lancet (British edition), 2013, Vol.381 (9871), p.1021-1028
13.
Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data
by Wang, Lixia, MS
The Lancet (British edition), 2014, Vol.383 (9934), p.2057-2064
14.
Current Concepts in the Management of Tuberculosis
by Sia, Irene G., MD, MSc
Mayo Clinic proceedings, 2011, Vol.86 (4), p.348-361
15.
Zoonotic tuberculosis in human beings caused by Mycobacterium bovis —a call for action
by Olea-Popelka, Francisco, Dr
The Lancet infectious diseases, 2016, Vol.17 (1), p.e21-e25
16.
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
by Russell, David G
Nature (London), 2000, Vol.406 (6797), p.735-738
17.
18.
P169 Latent tuberculosis infection screening of adult close contacts in london: a cost-utility analysis
by Hayama, M
Thorax, 2017, Vol.72 (Suppl 3), p.A174
19.
P221 Silicosis and mycobacterium disease: is it a problem in the uk?
by Hayton, C
Thorax, 2017, Vol.72 (Suppl 3), p.A203
20.
P161 Tuberculosis contact screening: will the 2016 guidelines lead to missed diagnoses?
by Prynn, J
Thorax, 2017, Vol.72 (Suppl 3), p.A171
